Vincent Johan Nijenhuis

Vincent Johan Nijenhuis

Auto-generated profile, based on publicly available information

Vincent Johan Nijenhuis

Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in American Heart Journal
Verified
Journal Article
Closed access
VNVincent Johan Nijenhuis
Vincent Johan Nijenhuis
NBNaoual Bennaghmouch
Naoual Bennaghmouch
MHMariella Hassell
Mariella Hassell
JBJan Baan
Jan Baan
JKJan Peter van Kuijk
Jan Peter van Kuijk
JBJurriën ten Berg
Jurriën ten Berg

13 March 2019 in Heart
Verified
Journal Article
Closed access
PDF file
VNVincent Johan Nijenhuis
Vincent Johan Nijenhuis
JBJorn Brouwer
Jorn Brouwer
LSLars Sondergaard
Lars Sondergaard
JCJean-Philippe Collet
Jean-Philippe Collet
EGErik Lerkevang Grove
Erik Lerkevang Grove
JBJurrien Maria Ten Berg
Jurrien Maria Ten Berg
This review provides a comprehensive overview of the available data on antithrombotic therapy after transcatheter aortic valve implantation (TAVI). In the absence of large randomised clinical trials, clinical practice is leaning towards evidence reported in other populations. Due to the greater risk of major bleeding associated with oral anticoagulation using a vitamin-K antagonist (VKA), antiplatelet therapy (APT) may be considered as the first-line treatment of patients undergoing TAVI. Overall, single rather than dual APT is preferred. However, dual APT should be considered in patients with a recent acute coronary syndrome (ie, within 6 months), complex coronary stenting, large aortic arch atheromas or previous non-cardioembolic stroke. Monotherapy with VKA should be considered if concomitant atrial fibrillation or any other indication for long-term oral anticoagulation is present. APT on top of VKA seems only reasonable in patients with recent acute coronary syndrome, extensive or recent coronary stenting or large aortic arch atheromas. A direct-acting oral anticoagulant may be considered if oral anticoagulation is indicated in the absence of contraindications. Initiation of VKA is indicated in clinical valve thrombosis, for example, with high transvalvular gradient, whereas the role of VKA in the case of subclinical leaflet thrombosis is currently uncertain.

8 September 2017 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
VNV. J. Nijenhuis
V. J. Nijenhuis
AAA. Alipour
A. Alipour
NWN. C. Wunderlich
N. C. Wunderlich
BRB. J. W. M. Rensing
B. J. W. M. Rensing
GGG. Gijsbers
G. Gijsbers
MSM. J. Swaans
M. J. Swaans
Structural heart interventions are guided by transoesophageal or intracardiac echocardiography (TEE/ICE). MicroTEE, developed for paediatric purposes, is smaller and therefore less invasive and traumatic, avoiding the need for general anaesthesia. We aimed to show feasibility of procedural guidance by comparing image quality of microTEE with standard TEE and ICE during adult transcatheter interventions, and assess the accuracy in obtaining left atrial appendage (LAA) measurements between the microTEE probe and standard TEE.

28 November 2013 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
VNV. J. Nijenhuis
V. J. Nijenhuis
PSP. R. Stella
P. R. Stella
JBJ. Baan
J. Baan
BBB. R. G. Brueren
B. R. G. Brueren
PJP. P. de Jaegere
P. P. de Jaegere
JBJ. M. Ten Berg
J. M. Ten Berg
Purpose To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). Methods For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. Results The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Conclusions Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach.

17 May 2017 in EP Europace
Verified
Journal Article
Closed access
PDF file
VNV.J. Nijenhuis
V.J. Nijenhuis
VDV.F. Van Dijk
V.F. Van Dijk
SCS.M. Chaldoupi
S.M. Chaldoupi
JBJ.C. Balt
J.C. Balt
JBJ.M. Ten Berg
J.M. Ten Berg
Transcatheter aortic valve implantation (TAVI) is frequently associated with cardiac conduction defects (CCD) requiring permanent pacemaker implantation (PPI). Although new-onset left bundle branch block (LBBB) is often seen, the rate of progression to severe CCD is unclear. We aimed to find clinical and electrocardiographic (ECG) parameters associated with severe CCD requiring PPI in patients with a new-onset LBBB after TAVI and assess its effect on clinical outcome. All consecutive patients undergoing TAVI who developed a new-onset LBBB were retrospectively analysed. We excluded patients with pre-existing bundle branch block or pacemaker. Patients were divided into two groups: with or without PPI after TAVI. We included 155 patients (50% female, 80 ± 7 years), of which 37 (24%) developed CCD requiring PPI, mainly due to a total atrioventricular block (n = 17; 46%). Cardiac conduction defects requiring PPI were associated with the following pre-existing parameters: atrial fibrillation (AF), the use of digoxin, CoreValve implantation, and left heart axis. Furthermore, it was associated with the following post-procedural parameters: left heart axis, lower mean heart rate, and prolonged PQ and QRS times. During follow-up, patients with PPI showed a lower mortality rate (11 vs. 29%, P = 0.03). In patients without PPI, mortality was lower in those with narrower QRS complex and transient LBBB. The severity and persistence of a new-onset LBBB after TAVI is associated with mortality. Cardiac conduction defects requiring PPI are associated with prior AF, the use of digoxin, CoreValve implantation, and a left heart axis. In these patients, PPI portends a better prognosis than no PPI.

1 May 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
VNVincent Johan Nijenhuis
Vincent Johan Nijenhuis
JPJoyce Peper
Joyce Peper
VVVeronique M.M. Vorselaars
Veronique M.M. Vorselaars
MSMartin J. Swaans
Martin J. Swaans
TKThom De Kroon
Thom De Kroon
JBJurrien M. Ten Berg
Jurrien M. Ten Berg